Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.54 |
| ▸ | PTGER1 | P34995 | 10/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180834 | 0.85 | SLC22A12 (0.47) | SLC22A12PTGER1CYP1A2TDP1MAPT | |
| SCHEMBL14289931 | 0.85 | P2RY14 (0.60) | PTGER1CYP1A2 | |
| SCHEMBL13693106 | 0.83 | PTGER1 (0.57) | PTGER1CYP1A2 | |
| SCHEMBL29831330 | 0.81 | P2RY14 (0.63) | PTGER1CYP1A2 | |
| SCHEMBL13693179 | 0.79 | PTGER1 (0.71) | PTGER1CYP1A2 | |
| SCHEMBL1137143 | 0.79 | PTGER1 (0.59) | PTGER1CYP1A2 | |
| SCHEMBL4160947 | 0.77 | PTGER1 (0.72) | PTGER1PTGER3 | |
| SCHEMBL4683754 | 0.75 | PTGER1 (0.78) | PTGER1CYP1A2 | |
| SCHEMBL14289988 | 0.74 | PTGER1 (0.58) | PTGER1CYP1A2 | |
| SCHEMBL14289951 | 0.74 | P2RY14 (0.52) | PTGER1CYP1A2PTGER3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022486-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-01-28 | — | — | US | disclosed |
| US-20100022486-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-01-28 | — | — | US | disclosed |
| US-20100022486-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-01-28 | — | — | US | disclosed |
| EP-2106398-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) | SmithKline Beecham Corporation (US) | 2009-10-07 | — | — | EP | disclosed |
| WO-2008074832-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE ( SCD) | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074832-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE ( SCD) | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022486-A1 | COMPOUNDS | SCD, CYP11B2, SCD5 | SLC22A12 1443/4885PTGER1 681/4885CYP1A2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.